Abstract
Many patients with tyrosinaemia type 1 have a mosaic pattern of fumarylacetoacetase (FAH) immunopositive or immunonegative nodules in liver tissue. This phenomenon has been explained by a spontaneous reversion of the mutation in one allele to a normal genotype, but only a few nodules have been examined. We now report on a Norwegian patient, compound heterozygous for the mutations IVS12g+5→a and G1009→A, with liver mosaicism, but with an immunopositive nodule in which both primary mutations were intact. In the immunopositive hepatocytes of this nodule, genetic analyses showed a new mutation, C1061→A, 6 bp upstream of the primary mutation IVS12g+5→a in the FAH gene. The splicing defect caused by the primary mutation is most likely suppressed by the new mutation due to improvement of the splicing site. In the same liver we demonstrate another nodule of regenerating immunopositive tissue due to reversion of one of the primary mutations to a normal genotype. Together with the original cells this makes a triple mosaicism of hepatocytes with one, two or three point mutations in the FAH gene.
Similar content being viewed by others
References
Goldsmith LA, Laberge C (1989) In: Scriver CR, Benita Y, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 547–562
Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94:1657–1661
Dreumont N, Poudrier JA, Bergeron A, Levy HL, Baklouti F, Tanguay RM (2001) A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation. BMC Genet 2:9
Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM (1998) Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab 64:119–125
Rootwelt H, Kristensen T, Berger R, Hoie K, Kvittingen EA (1994) Tyrosinemia type 1-complex splicing defects and a missense mutation in the fumarylacetoacetase gene. Hum Genet 94:235–239
Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91:1816–1821
Imyanitov EN, Grigoriev MY, Gorodinskaya VM, Kuligina ES, Pozharisski KM, Togo AV, Hanson KP (2001) Partial restoration of degraded DNA from archival paraffin-embedded tissues. Biotechniques 31:1000–1002
Burset M, Seledtsov IA, Solovyev VV (2000) Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res 28:4364–4375
Hirschhorn R (2003) In vivo reversion to normal of inherited mutations in humans. J Med Genet 40:721–728
Arredondo-Vega FX, Santisteban I, Richard E, Bali P, Koleilat M, Loubser M, Al Ghonaium A, Al Helali M, Hershfield MS (2002) Adenosine deaminase deficiency with mosaicism for a ‘second-site suppressor’ of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood 99:1005–1013
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bliksrud, Y.T., Brodtkorb, E., Andresen, P.A. et al. Tyrosinaemia type I—de novo mutation in liver tissue suppressing an inborn splicing defect. J Mol Med 83, 406–410 (2005). https://doi.org/10.1007/s00109-005-0648-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-005-0648-2